• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Immunome, Inc. - Common Stock (NQ:IMNM)

    23.11 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Jul 29, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 50
    Open 23.11
    Bid (Size) 22.43 (100)
    Ask (Size) 24.15 (100)
    Prev. Close 23.11
    Today's Range 23.11 - 23.11
    52wk Range 8.665 - 27.65
    Shares Outstanding 87,012,328
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-3050, an FAP-Targeted Radioligand Therapy, in Patients with FAP-Expressing Advanced Solid Tumors
    From Immunome, Inc.
    Via Business Wire
    News headline image
    What This Immunome Sale Means a Day Before a Big FDA Milestone ↗
    Barchas maintains 211,763 residual shares through direct and indirect holdings following execution under a Rule 10b5-1 trading plan adopted in March 2026. 
    Via The Motley Fool
    Topics Regulatory Compliance

    Performance

    YTD
    +11.0%
    +11.0%
    1 Month
    +9.8%
    +9.8%
    3 Month
    +0.7%
    +0.7%
    6 Month
    -6.6%
    -6.6%
    1 Year
    +118.0%
    +118.0%

    More News

    Read More
    News headline image
    Immunome Announces U.S. FDA Acceptance of New Drug Application for Varegacestat for the Treatment of Adults with Desmoid Tumors
    From Immunome, Inc.
    Via Business Wire
    News headline image
    Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Immunome, Inc.
    Via Business Wire
    News headline image
    Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-1617, a Potential First-in-Class ADC, in Patients with Advanced Solid Tumors
    From Immunome, Inc.
    Via Business Wire
    News headline image
    Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Immunome, Inc.
    Via Business Wire
    News headline image
    Immunome Announces Detailed Phase 3 RINGSIDE Data for Varegacestat in Adults with Progressing Desmoid Tumors at the 2026 ASCO Annual Meeting
    From Immunome, Inc.
    Via Business Wire
    News headline image
    Immunome to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
    From Immunome, Inc.
    Via Business Wire
    News headline image
    Immunome Reports First Quarter 2026 Financial Results and Provides Business Update
    From Immunome, Inc.
    Via Business Wire
    News headline image
    Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Immunome, Inc.
    Via Business Wire
    News headline image
    Immunome Announces Submission of New Drug Application to U.S. FDA for Varegacestat for the Treatment of Adults with Desmoid Tumors
    From Immunome, Inc.
    Via Business Wire
    News headline image
    Immunome Announces Oral Presentation of Phase 3 RINGSIDE Data at 2026 ASCO Annual Meeting
    From Immunome, Inc.
    Via Business Wire
    News headline image
    Immunome's Chief Scientist Trimmed His Stake. A Planned FDA Submission Tells You More ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Immunome, Inc.
    Via Business Wire
    News headline image
    ENAVATE's Zenas Bio Pharma add Is a Footnote — The Obexelimab Pipeline Is What to Watch ↗
    Via The Motley Fool
    News headline image
    Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Immunome, Inc.
    Via Business Wire
    News headline image
    Investment Manager Fully Exits Immunome Stock in $37.3 Million Sale, According to Latest SEC Filing ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Immunome Reports Full Year 2025 Financial Results and Provides Business Update
    From Immunome, Inc.
    Via Business Wire
    News headline image
    Immunome to Present at Upcoming Investor Conferences
    From Immunome, Inc.
    Via Business Wire
    News headline image
    Nurix Stock Is Down 6% This Past Year, but One Biotech Fund Still Boosted Its Bet By $63 Million ↗
    Via The Motley Fool
    News headline image
    Biotech-Focused Fund Adds $12 Million to Immunome Bet as Stock Surges 120% ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Investor Slashes $70 Million From Zymeworks as Stock Jumps 60% in a Year ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Biotech Investor Adds $3 Million to Krystal Biotech as Revenue Hits $389 Million in 2025 ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Biotech Fund Doubles Down With $49 Million Scholar Rock Buy as Shares Climb 26% ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Immunome, Inc.
    Via Business Wire

    Frequently Asked Questions

    Is Immunome, Inc. - Common Stock publicly traded?
    Yes, Immunome, Inc. - Common Stock is publicly traded.
    What exchange does Immunome, Inc. - Common Stock trade on?
    Immunome, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Immunome, Inc. - Common Stock?
    The ticker symbol for Immunome, Inc. - Common Stock is IMNM on the Nasdaq Stock Market
    What is the current price of Immunome, Inc. - Common Stock?
    The current price of Immunome, Inc. - Common Stock is 23.11
    When was Immunome, Inc. - Common Stock last traded?
    The last trade of Immunome, Inc. - Common Stock was at 07/29/26 04:00 PM ET
    What is the market capitalization of Immunome, Inc. - Common Stock?
    The market capitalization of Immunome, Inc. - Common Stock is 2.01B
    How many shares of Immunome, Inc. - Common Stock are outstanding?
    Immunome, Inc. - Common Stock has 2B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.